Breaking News, Collaborations & Alliances

Cytovance and Akshaya Enter Vaccine Collaboration

Partnership to focus on therapeutics for treatment of coronavirus and hepatitis B virus infections

By: Contract Pharma

Contract Pharma Staff

Cytovance Biologics, a contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has entered into a collaboration agreement with Akshaya Bio, a Canadian development stage biotechnology company to provide rapid access to clinical materials using Akshaya’s proprietary Chimigen Platform Technology for vaccine development for COVID-19 and HBV.   “Cytovance is driven to leverage innovative solutions and superior technologies t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters